伏立康唑治疗恶性肿瘤合并侵袭性真菌感染的临床观察  

The clinical observation of Voriconazole in the treatment of malignant tumor with invasive fungal infection

作　　者：熊慧华[1] 余忠贞[1] 石磊[1] 杨林[1] 于世英[1] 王波涌[2] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤中心,武汉430030 [2]武汉大学中南医院

出　　处：《临床内科杂志》2008年第10期669-671,共3页Journal of Clinical Internal Medicine

摘　　要：目的观察伏立康唑治疗恶性肿瘤患者合并侵袭性真菌感染的疗效和安全性。方法恶性肿瘤合并侵袭性真菌感染44例,随机分为国产伏立康唑组和伊曲康唑组,分别按照相应的指导用法治疗。结果伏立康唑组的治愈率和总有效率分别为68.2%和77.3%,不良反应率为27.3%;伊曲康唑组治愈率和总有效率分别为61.9%和76.2%,不良反应率为19.0%;两组的临床疗效和不良反应发生率比较差异均无显著性(均P>0.05)。结论对恶性肿瘤合并侵袭性真菌感染患者,应用国产伏立康唑治疗有效,安全性高,具有药物经济学价值。Objective To observe the efficacy and safety of voriconazole in the treatment of malignant tumor patients with invasive fungal infection. Methods Forty four malignant tumor patients complicated with invasive fungal infection were randomly enrolled in two groups. They were administered by Voriconazole and Itraconazole respectively. Results In Voriconazole group,the cure rate and overall clinical efficacy rate were 68.2% and 77.3% respectively. The rate of side effects in Voficonazole group was 27.3%. In Itraconazole group,the cure rate and overall clinical efficacy rate were 61.9% and 76.2% respectively. The adverse reaction rate was 19.0%. But there were no significant differences in overall cure rate, clinical efficacy rate and adverse reaction rate between two groups. Conclusion Voriconazole was effective and safe in the treatment of malignant tumor complicated by invasive fungal infection, which is more economical than Itraconazole.

关 键 词：恶性肿瘤 侵袭性真菌感染 伏立康唑 伊曲康唑 

分 类 号：R730.5[医药卫生—肿瘤] R519[医药卫生—临床医学]